Opem Biotech and Heluo Xintu Sign Strategic Cooperation Framework Agreement to Advance Cell Culture Innovation
Optimize
Cell Culture Technology Development and Biopharmaceutical Contract Development and Manufacturing Organization (CDMO) Provider
Renerval Therapeutics
Cell Therapy Technology Developer
On the morning of September 6, Shanghai OPM Biosciences Co., Ltd. (hereinafter referred to as "Optimize") and Renerval Therapeutics (Shanghai) Co., Ltd. (hereinafter referred to as "Renerval Therapeutics")Successfully Held Strategic Cooperation Framework Agreement Signing Ceremony。
Optimize and Renerval Therapeutics Hold Strategic Cooperation Framework Agreement Signing Ceremony
Optimize and Renerval Therapeutics have technological advantages in their respective fields,After in-depth exchanges and consultations in the early stage, both parties decided to reach a strategic cooperation intention on jointly developing and optimizing culture media, strengthening information exchange and resource integration, and jointly promoting innovation and development in the field of cell culture.
Cell culture technology, as the upstream core环节 of the biopharmaceutical industry, is an important driving force for the development of life sciences and healthcare. The strong collaboration between Renerval Therapeutics and Optimize will fully leverage and integrate the strengths and specialties of both parties.Accelerate the breakthrough and application of cell culture technology to provide more efficient, stable, and sustainable solutions for the biopharmaceutical industry.，WillTo bring more high-quality, affordable innovative therapies to patients worldwide and contribute to the health and well-being of all humanity.
About Renerval Therapeutics
Renerval Therapeutics, established in 2021, is a high-tech innovative enterprise aiming at iPSC directed differentiation, gene editing, large-scale cell product preparation, and cell therapy technology development.
Renerval Therapeutics focuses on cell-directed differentiation technology, dedicated to building an artificial blood preparation platform while simultaneously developing a world-leading regenerative medicine cell product development system. The company's R&D team has extensive research and industry experience in the fields of stem cells and translational medicine.
About Optimize
Optimize, founded in 2013 and listed on the STAR Market in 2022, is a high-tech biotechnology company focused on providing cell culture solutions and end-to-end CDMO services.
Optimize has cumulatively provided cell culture media products for 210+ global drug development pipelines with established pilot processes, successfully delivered 200+ biopharmaceutical development and production projects, and effectively assisted global partners in passing IND applications in both China and the U.S.
Source: Optimize
